

5. Literaturverzeichnis

1. Abbas AK, Murphy KM, and Sher A. Functional diversity of helper T lymphocytes. *Nature* 383: 787-793, 1996.
2. Adimoolam S and Ford JM. p53 and regulation of DNA damage recognition during nucleotide excision repair. *DNA Repair (Amst)* 2: 947-954, 2003.
3. Adrian Cabestre F, Moreau P, Riteau B, Ibrahim EC, Le Danff C, Dausset J, Rouas-Freiss N, Carosella ED, and Paul P. HLA-G expression in human melanoma cells: protection from NK cytotoxicity. *J Reprod Immunol* 43: 183-193, 1999.
4. Agarwal ML, Agarwal A, Taylor WR, and Stark GR. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. *Proc Natl Acad Sci U S A* 92: 8493-8497, 1995.
5. Alexander JP, Kudoh S, Melsop KA, Hamilton TA, Edinger MG, Tubbs RR, Sica D, Tuason L, Klein E, Bukowski RM, and et al. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. *Cancer Res* 53: 1380-1387, 1993.
6. Angevin E, Kremer F, Gaudin C, Hercend T, and Triebel F. Analysis of T-cell immune response in renal cell carcinoma: polarization to type 1-like differentiation pattern, clonal T-cell expansion and tumor-specific cytotoxicity. *Int J Cancer* 72: 431-440, 1997.
7. Asselin-Paturel C, Echchakir H, Carayol G, Gay F, Opolon P, Grunenwald D, Chouaib S, and Mami-Chouaib F. Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. *Int J Cancer* 77: 7-12, 1998.
8. Atkins D, Ferrone S, Schmahl GE, Storkel S, and Seliger B. Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? *J Urol* 171: 885-889, 2004.
9. Aulitzky W, Gastl G, Aulitzky WE, Herold M, Kemmler J, Mull B, Frick J, and Huber C. Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma. *J Clin Oncol* 7: 1875-1884, 1989.
10. Barinaga M. From bench top to bedside. *Science* 278: 1036-1039, 1997.
11. Baumann S, Krueger A, Kirchhoff S, and Krammer PH. Regulation of T cell apoptosis during the immune response. *Curr Mol Med* 2: 257-272, 2002.

12. Belldegrun A, Kasid A, Uppenkamp M, and Rosenberg SA. Lymphokine mRNA profile and functional analysis of a human CD4+ clone with unique antitumor specificity isolated from renal cell carcinoma ascitic fluid. *Cancer Immunol Immunother* 31: 1-10, 1990.
13. Berke G. The CTL's kiss of death. *Cell* 81: 9-12, 1995.
14. Bernstein C, Bernstein H, Payne CM, and Garewal H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. *Mutat Res* 511: 145-178, 2002.
15. Blay JY, Favrot MC, Negrier S, Combaret V, Chouaib S, Mercatello A, Kaemmerlen P, Franks CR, and Philip T. Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor. *Cancer Res* 50: 2371-2374, 1990.
16. Bonavida B. Immunomodulatory effect of tumor necrosis factor. *Biotherapy* 3: 127-133, 1991.
17. Bono AV and Lovisolo JA. Renal cell carcinoma--diagnosis and treatment: state of the art. *Eur Urol* 31 Suppl 1: 47-55, 1997.
18. Brasanac D, Muller CA, Muller GA, Hadzi-Dzokic J, and Markovic-Lipkovski J. HLA class I antigens expression in renal cell carcinoma: histopathological and clinical correlation. *J Exp Clin Cancer Res* 18: 505-510, 1999.
19. Brauch H, Weirich G, Brieger J, Glavac D, Rodl H, Eichinger M, Feurer M, Weidt E, Puranakanittha C, Neuhaus C, Pomer S, Brenner W, Schirmacher P, Storkel S, Rotter M, Masera A, Gugeler N, and Decker HJ. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. *Cancer Res* 60: 1942-1948, 2000.
20. Bromidge T and Lynas C. Relative levels of alternative transcripts of the ING1 gene and lack of mutations of p33/ING1 in haematological malignancies. *Leuk Res* 26: 631-635, 2002.
21. Brouwenstijn N, Gaugler B, Kruse KM, van der Spek CW, Mulder A, Osanto S, van den Eynde BJ, and Schrier PI. Renal-cell carcinoma-specific lysis by cytotoxic T-lymphocyte clones isolated from peripheral blood lymphocytes and tumor-infiltrating lymphocytes. *Int J Cancer* 68: 177-182, 1996.
22. Bukur J, Malenica B, Huber C, and Seliger B. Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response. *Hum Immunol* 64: 1081-1092, 2003.

23. Buzaid AC and Todd MB. Therapeutic options in renal cell carcinoma. *Semin Oncol* 16: 12-19, 1989.
24. Caignard A, Guillard M, Gaudin C, Escudier B, Triebel F, and Dietrich PY. In situ demonstration of renal-cell-carcinoma-specific T-cell clones. *Int J Cancer* 66: 564-570, 1996.
25. Campos EI, Cheung KJ, Jr., Murray A, Li S, and Li G. The novel tumour suppressor gene ING1 is overexpressed in human melanoma cell lines. *Br J Dermatol* 146: 574-580, 2002.
26. Campos EI, Martinka M, Mitchell DL, Dai DL, and Li G. Mutations of the ING1 tumor suppressor gene detected in human melanoma abrogate nucleotide excision repair. *Int J Oncol* 25: 73-80, 2004.
27. Chatenoud L SB, Bluestone JA Suppressor. T cells-they're back and critical for regulation of autoimmunity. *Immunol Rev* 182: 149-163, 2001.
28. Chen B, Campos EI, Crawford R, Martinka M, and Li G. Analyses of the tumour suppressor ING1 expression and gene mutation in human basal cell carcinoma. *Int J Oncol* 22: 927-931, 2003.
29. Chen F, Kishida T, Duh FM, Renbaum P, Orcutt ML, Schmidt L, and Zbar B. Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. *Cancer Res* 55: 4804-4807, 1995.
30. Chen L, Linsley PS, and Hellstrom KE. Costimulation of T cells for tumor immunity. *Immunol Today* 14: 483-486, 1993.
31. Chen L, Matsubara N, Yoshino T, Nagasaka T, Hoshizima N, Shirakawa Y, Naomoto Y, Isozaki H, Riabowol K, and Tanaka N. Genetic alterations of candidate tumor suppressor ING1 in human esophageal squamous cell cancer. *Cancer Res* 61: 4345-4349, 2001.
32. Cheng WS, Farrow GM, and Zincke H. The incidence of multicentricity in renal cell carcinoma. *J Urol* 146: 1221-1223, 1991.
33. Cheung KJ, Jr. and Li G. p33(ING1) enhances UVB-induced apoptosis in melanoma cells. *Exp Cell Res* 279: 291-298, 2002.
34. Cheung KJ, Jr. and Li G. The tumor suppressor ING1: structure and function. *Exp Cell Res* 268: 1-6, 2001.
35. Choi EY, Park WS, Jung KC, Chung DH, Bae YM, Kim TJ, Song HG, Kim SH, Ham DI, Hahn JH, Kim J, Kim K, Hwang TS, and Park SH. Thymocytes positively select thymocytes in human system. *Hum Immunol* 54: 15-20, 1997.

36. Choy JS, Tobe BT, Huh JH, and Kron SJ. Yng2p-dependent NuA4 histone H4 acetylation activity is required for mitotic and meiotic progression. *J Biol Chem* 276: 43653-43662, 2001.
37. Collis SJ, Swartz MJ, Nelson WG, and DeWeese TL. Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. *Cancer Res* 63: 1550-1554, 2003.
38. Constant SL BK. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. *Annu Rev Immunol* 15: 297-322, 1997.
39. Cozar JM, Canton J, Tallada M, Concha A, Cabrera T, Garrido F, and Ruiz-Cabello Osuna F. Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas. *Cancer Immunol Immunother* 54: 858-866, 2005.
40. Davies B, Hiby S, Gardner L, Loke YW, and King A. HLA-G expression by tumors. *Am J Reprod Immunol* 45: 103-107, 2001.
41. de Oliveira Pinto LM, Garcia S, Lecoer H, Rapp C, and Gougeon ML. Increased sensitivity of T lymphocytes to tumor necrosis factor receptor 1 (TNFR1)- and TNFR2-mediated apoptosis in HIV infection: relation to expression of Bcl-2 and active caspase-8 and caspase-3. *Blood* 99: 1666-1675, 2002.
42. de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, Johnson K, Kastelein R, Yssel H, and de Vries JE. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. *J Exp Med* 174: 915-924, 1991.
43. Dengjel J, Nastke MD, Gouttefangeas C, Gitsioudis G, Schoor O, Altenberend F, Muller M, Kramer B, Missiou A, Sauter M, Hennenlotter J, Wernet D, Stenzl A, Rammensee HG, Klingel K, and Stevanovic S. Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. *Clin Cancer Res* 12: 4163-4170, 2006.
44. DeSimone JN, Bengtsson U, Wang X, Lao XY, Redpath JL, and Stanbridge EJ. Complexity of the mechanisms of initiation and maintenance of DNA damage-induced G2-phase arrest and subsequent G1-phase arrest: TP53-dependent and TP53-independent roles. *Radiat Res* 159: 72-85, 2003.
45. Dörrschuck A SA, Schnürer E et al. CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression. *Blood* 104: 2591-2599, 2004.

46. Duan DR, Humphrey JS, Chen DY, Weng Y, Sukegawa J, Lee S, Gnarr JR, Linehan WM, and Klausner RD. Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. *Proc Natl Acad Sci U S A* 92: 6459-6463, 1995.
47. Edwards MJ, Anderson JA, Angel JR, and Harty JI. Spontaneous regression of primary and metastatic renal cell carcinoma. *J Urol* 155: 1385, 1996.
48. Elsässer-Beile U GT, Gierschner D, Schmoll B, Schultze-Seemann W, Wetterauer U and Schulte Mönning J. Semiquantitative analysis of Th1 and Th2 cytokine expression in CD3+/-, CD4+/-, and CD8+-renal cell carcinoma infiltrating lymphocytes. *Cancer Immunol Immunother* 48: 204-208, 1999.
49. Elsässer-Beile U, Kolble N, Grussenmeyer T, Schultze-Seemann W, Wetterauer U, Gallati H, Schulte Mönning J, and von Kleist S. Th1 and Th2 cytokine response patterns in leukocyte cultures of patients with urinary bladder, renal cell and prostate carcinomas. *Tumour Biol* 19: 470-476, 1998.
50. Elsässer-Beile U, Rindsfuser M, Grussenmeyer T, Schultze-Seemann W, and Wetterauer U. Enhanced expression of IFN-gamma mRNA in CD4(+) or CD8(+) tumour-infiltrating lymphocytes compared to peripheral lymphocytes in patients with renal cell cancer. *Br J Cancer* 83: 637-641, 2000.
51. Elsässer-Beile U, Wetterauer U, Schultze-Seemann W, Gallati H, Mönning JS, and von Kleist S. Analysis of the immune reactivity of infiltrating and peripheral lymphocytes from patients with renal cell carcinoma by measuring cytokine secretion. *Cancer Immunol Immunother* 42: 93-98, 1996.
52. Epstein RJ. Drug-induced DNA damage and tumor chemosensitivity. *J Clin Oncol* 8: 2062-2084, 1990.
53. Evans R, Duffy TM, and Kamdar SJ. Differential in situ expansion and gene expression of CD4+ and CD8+ tumor-infiltrating lymphocytes following adoptive immunotherapy in a murine tumor model system. *Eur J Immunol* 21: 1815-1819, 1991.
54. Feil G, Leipoldt M, Nelde HJ, Wunderer A, Wechsel HW, Kaiser P, and Bichler KH. Loss of chromosomes in clear cell renal cell carcinoma and in corresponding renal parenchyma. *Anticancer Res* 19: 1477-1482, 1999.
55. Feng X, Hara Y, and Riabowol K. Different HATS of the ING1 gene family. *Trends Cell Biol* 12: 532-538, 2002.

56. Feuerer M, Beckhove P, Bai L, Solomayer EF, Bastert G, Diel IJ, Pedain C, Oberniedermayr M, Schirmacher V, and Umansky V. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. *Nat Med* 7: 452-458, 2001.
57. Feuerer M, Beckhove P, Garbi N, Mahnke Y, Limmer A, Hommel M, Hammerling GJ, Kyewski B, Hamann A, Umansky V, and Schirmacher V. Bone marrow as a priming site for T-cell responses to blood-borne antigen. *Nat Med* 9: 1151-1157, 2003.
58. Feuerer M, Rocha M, Bai L, Umansky V, Solomayer EF, Bastert G, Diel IJ, and Schirmacher V. Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients. *Int J Cancer* 92: 96-105, 2001.
59. Filgueira L, Zuber M, Merlo A, Caetano V, Schultz E, Harder F, Spagnoli GC, and Heberer M. Cytokine gene transcription in renal cell carcinoma. *Br J Surg* 80: 1322-1325, 1993.
60. Finke JH, Rayman P, Alexander J, Edinger M, Tubbs RR, Connelly R, Pontes E, and Bukowski R. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma. *Cancer Res* 50: 2363-2370, 1990.
61. Finke JH, Rayman P, Edinger M, Tubbs RR, Stanley J, Klein E, and Bukowski R. Characterization of a human renal cell carcinoma specific cytotoxic CD8+ T cell line. *J Immunother* 11: 1-11, 1992.
62. Finke JH, Rayman P, Hart L, Alexander JP, Edinger MG, Tubbs RR, Klein E, Tuason L, and Bukowski RM. Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation. *J Immunother Emphasis Tumor Immunol* 15: 91-104, 1994.
63. Finke JH RP, George R, et al. Tumor-induced sensitivity to apoptosis in T cells from patients with renal cell carcinoma: role of nuclear factor-kappaB suppression. *Clin Cancer Res* 7: 940-946, 2001.
64. Finke JH ZA, Stanley J et al. Loss of T-cell-receptor zeta chain and p56lck in T-cell-infiltrating human renal-cell carcinoma. *Cancer Res* 53: 5613-5616, 1993.
65. Finke JH, Zea AH, Stanley J, Longo DL, Mizoguchi H, Tubbs RR, Wiltrout RH, O'Shea JJ, Kudoh S, Klein E, and et al. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. *Cancer Res* 53: 5613-5616, 1993.
66. Fischer CG. [Etiology, pathogenesis and therapy of renal cell carcinoma]. *Radiologe* 39: 343-349, 1999.

67. Fischer CG, Waechter W, Kraus S, Fuentecilla Perez E, Weidner W, and Dudeck J. Urologic tumors in the Federal Republic of Germany: data on 56,013 cases from hospital cancer registries. *Cancer* 82: 775-783, 1998.
68. Fridman WH and Tartour E. Macrophage- and lymphocyte-produced Th1 and Th2 cytokines in the tumour microenvironment. *Res Immunol* 149: 651-653, 1998.
69. Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, Masters JR, and Hickson ID. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. *Cancer Res* 51: 6592-6595, 1991.
70. Gajewski TF and Fallarino F. Rational development of tumour antigen-specific immunization in melanoma. *Ther Immunol* 2: 211-225, 1995.
71. Garkavtsev I, Boland D, Mai J, Wilson H, Veillette C, and Riabowol K. Specific monoclonal antibody raised against the p33ING1 tumor suppressor. *Hybridoma* 16: 537-540, 1997.
72. Garkavtsev I, Grigorian IA, Ossovskaya VS, Chernov MV, Chumakov PM, and Gudkov AV. The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control. *Nature* 391: 295-298, 1998.
73. Garkavtsev I, Kozin SV, Chernova O, Xu L, Winkler F, Brown E, Barnett GH, and Jain RK. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. *Nature* 428: 328-332, 2004.
74. Garkavtsev II. Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation. *Nat Genet* 23: 373, 1999.
75. Gastl G, Ebert T, Finstad CL, Sheinfeld J, Gomahr A, Aulitzky W, and Bander NH. Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma. *J Urol* 155: 361-367, 1996.
76. Gati A, Guerra N, Giron-Michel J, Azzarone B, Angevin E, Moretta A, Chouaib S, and Caignard A. Tumor cells regulate the lytic activity of tumor-specific cytotoxic t lymphocytes by modulating the inhibitory natural killer receptor function. *Cancer Res* 61: 3240-3244, 2001.
77. Girnita L, Girnita A, Brodin B, Xie Y, Nilsson G, Dricu A, Lundeberg J, Wejde J, Bartolazzi A, Wiman KG, and Larsson O. Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. *Cancer Res* 60: 5278-5283, 2000.

78. Gnjatic S, Atanackovic D, Jager E, Matsuo M, Selvakumar A, Altorki NK, Maki RG, Dupont B, Ritter G, Chen YT, Knuth A, and Old LJ. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. *Proc Natl Acad Sci U S A* 100: 8862-8867, 2003.
79. Gogusev J, Augusti M, Chretien Y, and Droz D. Interleukin-6 and TNF alpha production in human renal cell carcinoma. *Kidney Int* 44: 585-592, 1993.
80. Goldman M and Druet P. The TH1/TH2 concept and its relevance to renal disorders and transplantation immunity. *Nephrol Dial Transplant* 10: 1282-1284, 1995.
81. Goldstein NS. The current state of renal cell carcinoma grading. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). *Cancer* 80: 977-980, 1997.
82. Gozani O, Karuman P, Jones DR, Ivanov D, Cha J, Lugovskoy AA, Baird CL, Zhu H, Field SJ, Lessnick SL, Villasenor J, Mehrotra B, Chen J, Rao VR, Brugge JS, Ferguson CG, Payrastra B, Myszka DG, Cantley LC, Wagner G, Divecha N, Prestwich GD, and Yuan J. The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor. *Cell* 114: 99-111, 2003.
83. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K, and Scheurich P. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. *Cell* 83: 793-802, 1995.
84. Gu W and Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. *Cell* 90: 595-606, 1997.
85. Gunduz M, Ouchida M, Fukushima K, Hanafusa H, Etani T, Nishioka S, Nishizaki K, and Shimizu K. Genomic structure of the human ING1 gene and tumor-specific mutations detected in head and neck squamous cell carcinomas. *Cancer Res* 60: 3143-3146, 2000.
86. Gunduz M, Ouchida M, Fukushima K, Ito S, Jitsumori Y, Nakashima T, Nagai N, Nishizaki K, and Shimizu K. Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers. *Oncogene* 21: 4462-4470, 2002.
87. Gunia S, May M, Korb K, and Stosiek P. [Renal cell carcinoma. Comparative analysis of the prognostic significance of the WHO-classification and the Storkel's prognostic score]. *Urologe A* 43: 450-456, 2004.

88. Haitel A, Wiener HG, Baethge U, Marberger M, and Susani M. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. *Clin Cancer Res* 6: 1840-1844, 2000.
89. Haitel A, Wiener HG, Blaschitz U, Marberger M, and Susani M. Biologic behavior of and p53 overexpression in multifocal renal cell carcinoma of clear cell type: an immunohistochemical study correlating grading, staging, and proliferation markers. *Cancer* 85: 1593-1598, 1999.
90. Hara Y, Zheng Z, Evans SC, Malatjalian D, Riddell DC, Guernsey DL, Wang LD, Riabowol K, and Casson AG. ING1 and p53 tumor suppressor gene alterations in adenocarcinomas of the esophagogastric junction. *Cancer Lett* 192: 109-116, 2003.
91. Harper JW, Adami GR, Wei N, Keyomarsi K, and Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. *Cell* 75: 805-816, 1993.
92. Helbing CC, Veillette C, Riabowol K, Johnston RN, and Garkavtsev I. A novel candidate tumor suppressor, ING1, is involved in the regulation of apoptosis. *Cancer Res* 57: 1255-1258, 1997.
93. Herrlinger A, Schott G, Schafhauser W, and Schrott KM. [The significance of tumor diameter in renal cell carcinoma]. *Urologe A* 31: 70-75, 1992.
94. Hom SS, Topalian SL, Simonis T, Mancini M, and Rosenberg SA. Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction. *J Immunother* 10: 153-164, 1991.
95. Hoque MO, Kawamata H, Nakashiro K, Omotehara F, Hino S, Uchida D, Harada K, Begum NM, Yoshida H, Sato M, and Fujimori T. Dysfunction of the p53 tumor suppressor pathway in head and neck cancer. *Int J Oncol* 21: 119-126, 2002.
96. Hosaka N, Oyaizu N, Kaplan MH, Yagita H, and Pahwa S. Membrane and soluble forms of Fas (CD95) and Fas ligand in peripheral blood mononuclear cells and in plasma from human immunodeficiency virus-infected persons. *J Infect Dis* 178: 1030-1039, 1998.
97. Ibrahim EC, Guerra N, Lacombe MJ, Angevin E, Chouaib S, Carosella ED, Caignard A, and Paul P. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. *Cancer Res* 61: 6838-6845, 2001.

98. Ibrahim el C, Allory Y, Commo F, Gattegno B, Callard P, and Paul P. Altered pattern of major histocompatibility complex expression in renal carcinoma: tumor-specific expression of the nonclassical human leukocyte antigen-G molecule is restricted to clear cell carcinoma while up-regulation of other major histocompatibility complex antigens is primarily distributed in all subtypes of renal carcinoma. *Am J Pathol* 162: 501-508, 2003.
99. Igarashi T, Murakami S, Takahashi H, Matsuzaki O, and Shimazaki J. Changes on distribution of CD4+/CD45RA- and CD8+/CD11- cells in tumor-infiltrating lymphocytes of renal cell carcinoma associated with tumor progression. *Eur Urol* 22: 323-328, 1992.
100. Ikemoto S, Yoshida N, Narita K, Wada S, Kishimoto T, Sugimura K, and Nakatani T. Role of tumor-associated macrophages in renal cell carcinoma. *Oncol Rep* 10: 1843-1849, 2003.
101. Iliopoulos O, Kibel A, Gray S, and Kaelin WG, Jr. Tumour suppression by the human von Hippel-Lindau gene product. *Nat Med* 1: 822-826, 1995.
102. Innocente SA, Abrahamson JL, Cogswell JP, and Lee JM. p53 regulates a G2 checkpoint through cyclin B1. *Proc Natl Acad Sci U S A* 96: 2147-2152, 1999.
103. Ishida H, Irie K, Itoh T, Furukawa T, and Tokunaga O. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. *Cancer* 80: 1034-1045, 1997.
104. Ito K, Kinjo K, Nakazato T, Ikeda Y, and Kizaki M. Expression and sequence analyses of p33(ING1) gene in myeloid leukemia. *Am J Hematol* 69: 141-143, 2002.
105. Jäger D SE, Scanlan MJ, Güre AO, Jäger E, Knuth A. Cancer-Testis Antigens and ING1 Tumor Suppressor Gene Product Are Breast Cancer Antigens: Characterization of Tissue-specific ING1 Transcripts and a Homologue Gene1. *Cancer Research* 59, 1999.
106. Jakobsen MK, Restifo NP, Cohen PA, Marincola FM, Cheshire LB, Linehan WM, Rosenberg SA, and Alexander RB. Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line. *J Immunother Emphasis Tumor Immunol* 17: 222-228, 1995.
107. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, and Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. *Nature* 421: 852-856, 2003.
108. Jeremias I, Herr I, Boehler T, and Debatin KM. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. *Eur J Immunol* 28: 143-152, 1998.

109. Kameyama K, Huang CL, Liu D, Masuya D, Nakashima T, Sumitomo S, Takami Y, Kinoshita M, and Yokomise H. Reduced ING1b gene expression plays an important role in carcinogenesis of non-small cell lung cancer patients. *Clin Cancer Res* 9: 4926-4934, 2003.
110. Kataoka H, Bonnefin P, Vieyra D, Feng X, Hara Y, Miura Y, Joh T, Nakabayashi H, Vaziri H, Harris CC, and Riabowol K. ING1 represses transcription by direct DNA binding and through effects on p53. *Cancer Res* 63: 5785-5792, 2003.
111. Kawakami Y, Nabeshima S, Furusyo N, Sawayama Y, Hayashi J, and Kashiwagi S. Increased frequency of interferon-gamma-producing peripheral blood CD4+ T cells in chronic hepatitis C virus infection. *Am J Gastroenterol* 95: 227-232, 2000.
112. Kehrl JH. Transforming growth factor-beta: an important mediator of immunoregulation. *Int J Cell Cloning* 9: 438-450, 1991.
113. Keilholz U and Eggermont AM. The emerging role of cytokines in the treatment of advanced melanoma. For the EORTC Melanoma Cooperative Group. *Oncology* 58: 89-95, 2000.
114. Keilholz U, Stoter G, Punt CJ, Scheibenbogen C, Lejeune F, and Eggermont AM. Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. *Cancer J Sci Am* 3 Suppl 1: S22-28, 1997.
115. Kichina JV, Rauth S, Das Gupta TK, and Gudkov AV. Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53. *Oncogene* 22: 4911-4917, 2003.
116. Kliem V, Kolditz M, Behrend M, Ehlerding G, Pichlmayr R, Koch KM, and Brunkhorst R. Risk of renal cell carcinoma after kidney transplantation. *Clin Transplant* 11: 255-258, 1997.
117. Kobayashi H, Omiya R, Ruiz M, Huarte E, Sarobe P, Lasarte JJ, Herraiz M, Sangro B, Prieto J, Borrás-Cuesta F, and Celis E. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. *Clin Cancer Res* 8: 3219-3225, 2002.
118. Kovacs G, Emanuel A, Neumann HP, and Kung HF. Cytogenetics of renal cell carcinomas associated with von Hippel-Lindau disease. *Genes Chromosomes Cancer* 3: 256-262, 1991.
119. Kovacs G, Fuzesi L, Emanuel A, and Kung HF. Cytogenetics of papillary renal cell tumors. *Genes Chromosomes Cancer* 3: 249-255, 1991.

120. Kovacs G and Kung HF. Nonhomologous chromatid exchange in hereditary and sporadic renal cell carcinomas. *Proc Natl Acad Sci U S A* 88: 194-198, 1991.
121. Kowalczyk D, Skorupski W, Kwias Z, and Nowak J. Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma. *Br J Urol* 80: 543-547, 1997.
122. Krammer PH. CD95's deadly mission in the immune system. *Nature* 407: 789-795, 2000.
123. Krippner-Heidenreich A, Tubing F, Bryde S, Willi S, Zimmermann G, and Scheurich P. Control of receptor-induced signaling complex formation by the kinetics of ligand/receptor interaction. *J Biol Chem* 277: 44155-44163, 2002.
124. Krishnamurthy J, Kannan K, Feng J, Mohanprasad BK, Tsuchida N, and Shanmugam G. Mutational analysis of the candidate tumor suppressor gene ING1 in Indian oral squamous cell carcinoma. *Oral Oncol* 37: 222-224, 2001.
125. Kunisch-Hoppe M, Hoppe M, Bohle RM, Rauber K, Weimar B, Friemann S, Stahl U, and Rau WS. Metastatic RCC arising in a transplant kidney. *Eur Radiol* 8: 1441-1443, 1998.
126. Lakin ND and Jackson SP. Regulation of p53 in response to DNA damage. *Oncogene* 18: 7644-7655, 1999.
127. LaSalle JM, Tolentino PJ, Freeman GJ, Nadler LM, and Hafler DA. Early signaling defects in human T cells anergized by T cell presentation of autoantigen. *J Exp Med* 176: 177-186, 1992.
128. Le Bouteiller P and Blaschitz A. The functionality of HLA-G is emerging. *Immunol Rev* 167: 233-244, 1999.
129. Le J and Vilcek J. Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. *Lab Invest* 56: 234-248, 1987.
130. Lefebvre S, Antoine M, Uzan S, McMaster M, Dausset J, Carosella ED, and Paul P. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. *J Pathol* 196: 266-274, 2002.
131. Legha SS. Interferons in the treatment of malignant melanoma. A review of recent trials. *Cancer* 57: 1675-1677, 1986.

132. Leibund Gut-Landmann S WJ, Krawczyk M. Mini-review: specificity and expression of CIITA, the master regulator of MHC class II genes. *Eur J Immunol* 34: 1513-1525, 2004.
133. Leung KM, Po LS, Tsang FC, Siu WY, Lau A, Ho HT, and Poon RY. The candidate tumor suppressor ING1b can stabilize p53 by disrupting the regulation of p53 by MDM2. *Cancer Res* 62: 4890-4893, 2002.
134. Levine AJ. p53, the cellular gatekeeper for growth and division. *Cell* 88: 323-331, 1997.
135. Levings MK, Bacchetta R, Schulz U, and Roncarolo MG. The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells. *Int Arch Allergy Immunol* 129: 263-276, 2002.
136. Levinson AK, Johnson DE, Strong LC, Pathak S, Huff V, and Saunders GF. Familial renal cell carcinoma: hereditary or coincidental? *J Urol* 144: 849-851, 1990.
137. Li G and Ho VC. p53-dependent DNA repair and apoptosis respond differently to high- and low-dose ultraviolet radiation. *Br J Dermatol* 139: 3-10, 1998.
138. Li M, Luo J, Brooks CL, and Gu W. Acetylation of p53 inhibits its ubiquitination by Mdm2. *J Biol Chem* 277: 50607-50611, 2002.
139. Ljungberg B. Prognostic factors in renal cell carcinoma. *Scand J Surg* 93: 118-125, 2004.
140. Ljungberg B. Prognostic factors in renal cell carcinoma. *Urologe A* 43 Suppl 3: 119-120, 2004.
141. Ljungberg B, Bozoky B, Kovacs G, Stattin P, Farrelly E, Nylander K, and Landberg G. p53 expression in correlation to clinical outcome in patients with renal cell carcinoma. *Scand J Urol Nephrol* 35: 15-20, 2001.
142. Ljungberg B, Joanssen H, and Stenling R. Prognostic factors in renal cell carcinoma. *Int Urol Nephrol* 20: 115-121, 1988.
143. Lombardi G, Hargreaves R, Sidhu S, Imami N, Lightstone L, Fuller-Espie S, Ritter M, Robinson P, Tarnok A, and Lechler R. Antigen presentation by T cells inhibits IL-2 production and induces IL-4 release due to altered cognate signals. *J Immunol* 156: 2769-2775, 1996.
144. Lotze MT, Rubin JT, Carty S, Edington H, Ferson P, Landreneau R, Pippin B, Posner M, Rosenfelder D, Watson C, and et al. Gene therapy of cancer: a pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response. *Hum Gene Ther* 5: 41-55, 1994.

145. Lum JJ, Pilon AA, Sanchez-Dardon J, Phenix BN, Kim JE, Mihowich J, Jamison K, Hawley-Foss N, Lynch DH, and Badley AD. Induction of cell death in human immunodeficiency virus-infected macrophages and resting memory CD4 T cells by TRAIL/Apo2l. *J Virol* 75: 11128-11136, 2001.
146. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, and Gu W. Negative control of p53 by Sir2alpha promotes cell survival under stress. *Cell* 107: 137-148, 2001.
147. Luo J, Su F, Chen D, Shiloh A, and Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. *Nature* 408: 377-381, 2000.
148. Mach B, Steimle V, Martinez-Soria E, and Reith W. Regulation of MHC class II genes: lessons from a disease. *Annu Rev Immunol* 14: 301-331, 1996.
149. Maeurer MJ, Martin DM, Castelli C, Elder E, Leder G, Storkus WJ, and Lotze MT. Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. *Cancer Immunol Immunother* 41: 111-121, 1995.
150. Maisse C, Guerrieri P, and Melino G. p73 and p63 protein stability: the way to regulate function? *Biochem Pharmacol* 66: 1555-1561, 2003.
151. Mani S, Todd M, and Poo WJ. Recombinant beta-interferon in the treatment of patients with metastatic renal cell carcinoma. *Am J Clin Oncol* 19: 187-189, 1996.
152. Marincola FM, Jaffee EM, Hicklin DJ, and Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. *Adv Immunol* 74: 181-273, 2000.
153. Matsui S, Ahlers JD, Vortmeyer AO, Terabe M, Tsukui T, Carbone DP, Liotta LA, and Berzofsky JA. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. *J Immunol* 163: 184-193, 1999.
154. Mazzocchi A, Belli F, Mascheroni L, Vegetti C, Parmiani G, and Anichini A. Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients. *Int J Cancer* 58: 330-339, 1994.

155. Miescher S, Stoeck M, Qiao L, Barras C, Barrelet L, and von Flidner V. Proliferative and cytolytic potentials of purified human tumor-infiltrating T lymphocytes. Impaired response to mitogen-driven stimulation despite T-cell receptor expression. *Int J Cancer* 42: 659-666, 1988.
156. Mikami T, Yanagisawa N, Baba H, Koike M, and Okayasu I. Association of Bcl-2 protein expression with gallbladder carcinoma differentiation and progression and its relation to apoptosis. *Cancer* 85: 318-325, 1999.
157. Miki S IM, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T, Hirano T, Kishimoto T. Interleukin-6 functions as an in vitro autocrine growth factor in renal cell carcinomas. *FEBS Lett* 250: 607-610, 1989.
158. Mirghomizadeh F, Kupka S, and Blin N. Assessing genetic heterogeneity of renal cell tumors. *Anticancer Res* 19: 1467-1470, 1999.
159. Mitropoulos D, Kooi S, Rodriguez-Villanueva J, and Platsoucas CD. Characterization of fresh (uncultured) tumour-infiltrating lymphocytes (TIL) and TIL-derived T cell lines from patients with renal cell carcinoma. *Clin Exp Immunol* 97: 321-327, 1994.
160. Moretta A, Biassoni R, Bottino C, Pende D, Vitale M, Poggi A, Mingari MC, and Moretta L. Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. *Immunol Rev* 155: 105-117, 1997.
161. Morita R, Hikiji K, Yamakawa K, and Nakamura Y. [Tumor suppressor genes associated with development of human renal cell carcinoma]. *Nippon Rinsho* 50: 3100-3105, 1992.
162. Mosmann TR and Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. *Annu Rev Immunol* 7: 145-173, 1989.
163. Muss HB. The use of interferon in renal cell carcinoma. *Eur J Cancer* 27 Suppl 4: S84-87, 1991.
164. Nagai H, Hara I, Horikawa T, Oka M, Kamidono S, and Ichihashi M. Elimination of CD4(+) T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration. *J Invest Dermatol* 115: 1059-1064, 2000.
165. Nagashima M, Shiseki M, Miura K, Hagiwara K, Linke SP, Pedeux R, Wang XW, Yokota J, Riabowol K, and Harris CC. DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53. *Proc Natl Acad Sci U S A* 98: 9671-9676, 2001.

166. Nagashima M, Shiseki M, Pedoux RM, Okamura S, Kitahama-Shiseki M, Miura K, Yokota J, and Harris CC. A novel PHD-finger motif protein, p47ING3, modulates p53-mediated transcription, cell cycle control, and apoptosis. *Oncogene* 22: 343-350, 2003.
167. Nagoshi M, Goedegebuure PS, Burger UL, Sadanaga N, Chang MP, and Eberlein TJ. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes. *J Immunol* 160: 334-344, 1998.
168. Nagoshi M, Sadanaga N, Joo HG, Goedegebuure PS, and Eberlein TJ. Tumor-specific cytokine release by donor T cells induces an effective host anti-tumor response through recruitment of host naive antigen presenting cells. *Int J Cancer* 80: 308-314, 1999.
169. Nakagomi H, Pisa P, Pisa EK, Yamamoto Y, Halapi E, Backlin K, Juhlin C, and Kiessling R. Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. *Int J Cancer* 63: 366-371, 1995.
170. Nakamura S, Gomyo Y, Roth JA, and Mukhopadhyay T. C-terminus of p53 is required for G(2) arrest. *Oncogene* 21: 2102-2107, 2002.
171. Nebl T, Pestonjamas KN, Leszyk JD, Crowley JL, Oh SW, and Luna EJ. Proteomic analysis of a detergent-resistant membrane skeleton from neutrophil plasma membranes. *J Biol Chem* 277: 43399-43409, 2002.
172. Nishimura Y, Chen YZ, Uemura Y, Tanaka Y, Tsukamoto H, Kanai T, Yokomizo H, Yun C, Matsuoka T, Irie A, and Matsushita S. Degenerate recognition and response of human CD4+ Th cell clones: implications for basic and applied immunology. *Mol Immunol* 40: 1089-1094, 2004.
173. Nissenkorn I and Bernheim J. Multicentricity in renal cell carcinoma. *J Urol* 153: 620-622, 1995.
174. Nouman GS, Anderson JJ, Crosier S, Shrimankar J, Lunec J, and Angus B. Downregulation of nuclear expression of the p33(ING1b) inhibitor of growth protein in invasive carcinoma of the breast. *J Clin Pathol* 56: 507-511, 2003.
175. Nouman GS, Anderson JJ, Lunec J, and Angus B. The role of the tumour suppressor p33 ING1b in human neoplasia. *J Clin Pathol* 56: 491-496, 2003.
176. Nouman GS, Anderson JJ, Mathers ME, Leonard N, Crosier S, Lunec J, and Angus B. Nuclear to cytoplasmic compartment shift of the p33ING1b tumour suppressor protein is associated with malignancy in melanocytic lesions. *Histopathology* 40: 360-366, 2002.

177. Nouman GS, Anderson JJ, Wood KM, Lunec J, Hall AG, Reid MM, and Angus B. Loss of nuclear expression of the p33(ING1b) inhibitor of growth protein in childhood acute lymphoblastic leukaemia. *J Clin Pathol* 55: 596-601, 2002.
178. Oberneder R HA. Operative und immunmodulatorische Therapie des Nierenzellkarzinoms. *Remission* 1-99: 3-5, 1999.
179. Ohgi T, Masaki T, Nakai S, Morishita A, Yukimasa S, Nagai M, Miyauchi Y, Funaki T, Kurokohchi K, Watanabe S, and Kuriyama S. Expression of p33(ING1) in hepatocellular carcinoma: relationships to tumour differentiation and cyclin E kinase activity. *Scand J Gastroenterol* 37: 1440-1448, 2002.
180. Ohmori M, Nagai M, Tasaka T, Koeffler HP, Toyama T, Riabowol K, and Takahara J. Decreased expression of p33ING1 mRNA in lymphoid malignancies. *Am J Hematol* 62: 118-119, 1999.
181. Oki E, Maehara Y, Tokunaga E, Kakeji Y, and Sugimachi K. Reduced expression of p33(ING1) and the relationship with p53 expression in human gastric cancer. *Cancer Lett* 147: 157-162, 1999.
182. Olive C, Cheung C, Nicol D, and Falk MC. Expression of cytokine mRNA transcripts in renal cell carcinoma. *Immunol Cell Biol* 76: 357-362, 1998.
183. Olive C, Nicol D, and Falk MC. Characterisation of gamma delta T cells in renal cell carcinoma patients by polymerase chain reaction analysis of T cell receptor transcripts. *Cancer Immunol Immunother* 44: 27-34, 1997.
184. Oliver RT, Nouri AM, Crosby D, Iles RL, Navarette C, Martin J, Bodmer W, and Festenstein H. Biological significance of beta hCG, HLA and other membrane antigen expression on bladder tumours and their relationship to tumour infiltrating lymphocytes (TIL). *J Immunogenet* 16: 381-390, 1989.
185. Ortelgel JW, Staren ED, Faber LP, Warren WH, and Braun DP. Cytokine biosynthesis by tumor-infiltrating T lymphocytes from human non-small-cell lung carcinoma. *Cancer Immunol Immunother* 48: 627-634, 2000.
186. Ossendorp F, Mengede E, Camps M, Filius R, and Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. *J Exp Med* 187: 693-702, 1998.
187. Parmiani G, Anichini A, and Fossati G. Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy? *J Natl Cancer Inst* 82: 361-370, 1990.

188. Paul P, Cabestre FA, Le Gal FA, Khalil-Daher I, Le Danff C, Schmid M, Mercier S, Avril MF, Dausset J, Guillet JG, and Carosella ED. Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. *Cancer Res* 59: 1954-1960, 1999.
189. Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, Avril MF, Dausset J, Guillet JG, and Carosella ED. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. *Proc Natl Acad Sci U S A* 95: 4510-4515, 1998.
190. Pende D, Sivori S, Accame L, Pareti L, Falco M, Geraghty D, Le Bouteiller P, Moretta L, and Moretta A. HLA-G recognition by human natural killer cells. Involvement of CD94 both as inhibitory and as activating receptor complex. *Eur J Immunol* 27: 1875-1880, 1997.
191. Pepe S, Ruggiero A, D'Acquisto M, De Laurentiis M, De Placido S, Sandomenico C, Staibano S, De Rosa G, Lucariello A, D'Armiento M, and Bianco AR. Nuclear DNA content-derived parameters correlated with heterogeneous expression of p53 and bcl-2 proteins in clear cell renal carcinomas. *Cancer* 89: 1065-1075, 2000.
192. Pichler WJ and Wyss-Coray T. T cells as antigen-presenting cells. *Immunol Today* 15: 312-315, 1994.
193. Pisa P, Halapi E, Pisa EK, Gerdin E, Hising C, Bucht A, Gerdin B, and Kiessling R. Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. *Proc Natl Acad Sci U S A* 89: 7708-7712, 1992.
194. Pomer S and Staehler G. [Traditional and future criteria for progression in renal cell carcinoma. Molecular biology and clinical aspects]. *Urologe A* 35: 254-262, 1996.
195. Porter LA and Donoghue DJ. Cyclin B1 and CDK1: nuclear localization and upstream regulators. *Prog Cell Cycle Res* 5: 335-347, 2003.
196. Rayman P, Wesa AK, Richmond AL, Das T, Biswas K, Raval G, Storkus WJ, Tannenbaum C, Novick A, Bukowski R, and Finke J. Effect of renal cell carcinomas on the development of type 1 T-cell responses. *Clin Cancer Res* 10: 6360S-6366S, 2004.
197. Real LM, Cabrera T, Collado A, Jimenez P, Garcia A, Ruiz-Cabello F, and Garrido F. Expression of HLA G in human tumors is not a frequent event. *Int J Cancer* 81: 512-518, 1999.
198. Rebmann V, Pfeiffer K, Passler M, Ferrone S, Maier S, Weiss E, and Grosse-Wilde H. Detection of soluble HLA-G molecules in plasma and amniotic fluid. *Tissue Antigens* 53: 14-22, 1999.

199. Romagnani S. The Th1/Th2 paradigm. *Immunol Today* 18: 263-266, 1997.
200. Saito A, Furukawa T, Fukushige S, Koyama S, Hoshi M, Hayashi Y, and Horii A. p24/ING1-ALT1 and p47/ING1-ALT2, distinct alternative transcripts of p33/ING1. *J Hum Genet* 45: 177-181, 2000.
201. Saito T, Dworacki G, Gooding W, Lotze MT, and Whiteside TL. Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma. *Clin Cancer Res* 6: 1351-1364, 2000.
202. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, and Appella E. DNA damage activates p53 through a phosphorylation-acetylation cascade. *Genes Dev* 12: 2831-2841, 1998.
203. Sanchez-Carbayo M, Socci ND, Lozano JJ, Li W, Charytonowicz E, Belbin TJ, Prystowsky MB, Ortiz AR, Childs G, and Cordon-Cardo C. Gene discovery in bladder cancer progression using cDNA microarrays. *Am J Pathol* 163: 505-516, 2003.
204. Sanchez-Cespedes M, Okami K, Cairns P, and Sidransky D. Molecular analysis of the candidate tumor suppressor gene ING1 in human head and neck tumors with 13q deletions. *Genes Chromosomes Cancer* 27: 319-322, 2000.
205. Sarela AI, Farmery SM, Markham AF, and Guillou PJ. The candidate tumour suppressor gene, ING1, is retained in colorectal carcinomas. *Eur J Cancer* 35: 1264-1267, 1999.
206. Satyaraj E, Rath S, and Bal V. Induction of tolerance in freshly isolated alloreactive T cells by activated T cell stimulators is not due to the absence of CD28-B7 interaction. *J Immunol* 155: 4669-4675, 1995.
207. Schendel DJ, Gansbacher B, Oberneder R, Kriegmair M, Hofstetter A, Riethmuller G, and Segurado OG. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. *J Immunol* 151: 4209-4220, 1993.
208. Schoof DD, Terashima Y, Peoples GE, Goedegebuure PS, Andrews JV, Richie JP, and Eberlein TJ. CD4+ T cell clones isolated from human renal cell carcinoma possess the functional characteristics of Th2 helper cells. *Cell Immunol* 150: 114-123, 1993.
209. Scott M, Boisvert FM, Vieyra D, Johnston RN, Bazett-Jones DP, and Riabowol K. UV induces nucleolar translocation of ING1 through two distinct nucleolar targeting sequences. *Nucleic Acids Res* 29: 2052-2058, 2001.

210. Scott M, Bonnefin P, Vieyra D, Boisvert FM, Young D, Bazett-Jones DP, and Riabowol K. UV-induced binding of ING1 to PCNA regulates the induction of apoptosis. *J Cell Sci* 114: 3455-3462, 2001.
211. Seliger B, Abken H, and Ferrone S. HLA-G and MIC expression in tumors and their role in anti-tumor immunity. *Trends Immunol* 24: 82-87, 2003.
212. Seliger B, Hohne A, Knuth A, Bernhard H, Ehring B, Tampe R, and Huber C. Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. *Clin Cancer Res* 2: 1427-1433, 1996.
213. Seo N, Hayakawa S, Takigawa M, and Tokura Y. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity. *Immunology* 103: 449-457, 2001.
214. Shimada H, Liu TL, Ochiai T, Shimizu T, Haupt Y, Hamada H, Abe T, Oka M, Takiguchi M, and Hiwasa T. Facilitation of adenoviral wild-type p53-induced apoptotic cell death by overexpression of p33(ING1) in T.Tn human esophageal carcinoma cells. *Oncogene* 21: 1208-1216, 2002.
215. Shimada Y, Saito A, Suzuki M, Takahashi E, and Horie M. Cloning of a novel gene (ING1L) homologous to ING1, a candidate tumor suppressor. *Cytogenet Cell Genet* 83: 232-235, 1998.
216. Shinoura N, Muramatsu Y, Nishimura M, Yoshida Y, Saito A, Yokoyama T, Furukawa T, Horii A, Hashimoto M, Asai A, Kirino T, and Hamada H. Adenovirus-mediated transfer of p33ING1 with p53 drastically augments apoptosis in gliomas. *Cancer Res* 59: 5521-5528, 1999.
217. Shiseki M, Nagashima M, Pedeux RM, Kitahama-Shiseki M, Miura K, Okamura S, Onogi H, Higashimoto Y, Appella E, Yokota J, and Harris CC. p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. *Cancer Res* 63: 2373-2378, 2003.
218. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. *Oncogene* 22: 7265-7279, 2003.
219. Sidransky D and Hollstein M. Clinical implications of the p53 gene. *Annu Rev Med* 47: 285-301, 1996.
220. Slaton JW, Benedict WF, and Dinney CP. P53 in bladder cancer: mechanism of action, prognostic value, and target for therapy. *Urology* 57: 852-859, 2001.

221. Sloand EM, Young NS, Kumar P, Weichold FF, Sato T, and Maciejewski JP. Role of Fas ligand and receptor in the mechanism of T-cell depletion in acquired immunodeficiency syndrome: effect on CD4+ lymphocyte depletion and human immunodeficiency virus replication. *Blood* 89: 1357-1363, 1997.
222. Steinbach F, Stockle M, Riedmiller H, Weingartner K, and Hohenfellner R. Tumor enucleation of renal cell carcinoma: operative technique, DNA cytometry results, complications. *Prog Clin Biol Res* 370: 1-7, 1991.
223. Steinbach F, Thuroff JW, Stockle M, Furrer A, Riedmiller H, Kiewel R, and Hohenfellner R. [Organ-preserving surgery of renal cell carcinoma. The surgical technic, results and complications]. *Dtsch Med Wochenschr* 116: 121-127, 1991.
224. Storkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG, Darson M, Delahunt B, and Iczkowski K. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). *Cancer* 80: 987-989, 1997.
225. Storkel S and Jacobi GH. [Classification, histogenesis, and prognosis of renal cell carcinoma and renal oncocytoma]. *Verh Dtsch Ges Pathol* 73: 321-338, 1989.
226. Storkel S, Thoenes W, Jacobi GH, Engelmann U, and Lippold R. Prognostic parameters of renal cell carcinoma. *Eur Urol* 18 Suppl 2: 36-37, 1990.
227. Storkel S, Thoenes W, Jacobi GH, and Lippold R. [Prognostic parameters in renal cell carcinoma--a new approach. 1989.]. *Aktuelle Urol* 35: 18-21, 2004.
228. Sun B, Wu Z, Ruan Y, Yang M, and Liu B. P21WAF1/Cip1 gene expression in primary human hepatocellular carcinoma and its relationship with P53 gene mutation. *J Tongji Med Univ* 19: 1-5, 1999.
229. Taams LS, van Eden W, and Wauben MH. Antigen presentation by T cells versus professional antigen-presenting cells (APC): differential consequences for T cell activation and subsequent T cell-APC interactions. *Eur J Immunol* 29: 1543-1550, 1999.
230. Tada T, Ohzeki S, Utsumi K, Takiuchi H, Muramatsu M, Li XF, Shimizu J, Fujiwara H, and Hamaoka T. Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. *J Immunol* 146: 1077-1082, 1991.

231. Takahashi M, Seki N, Ozaki T, Kato M, Kuno T, Nakagawa T, Watanabe K, Miyazaki K, Ohira M, Hayashi S, Hosoda M, Tokita H, Mizuguchi H, Hayakawa T, Todo S, and Nakagawara A. Identification of the p33(ING1)-regulated genes that include cyclin B1 and proto-oncogene DEK by using cDNA microarray in a mouse mammary epithelial cell line NMuMG. *Cancer Res* 62: 2203-2209, 2002.
232. Takenawa J, Kaneko Y, Fukumoto M, Fukatsu A, Hirano T, Fukuyama H, Nakayama H, Fujita J, and Yoshida O. Enhanced expression of interleukin-6 in primary human renal cell carcinomas. *J Natl Cancer Inst* 83: 1668-1672, 1991.
233. Tallen G, Kaiser I, Krabbe S, Lass U, Hartmann C, Henze G, Riabowol K, and von Deimling A. No ING1 mutations in human brain tumours but reduced expression in high malignancy grades of astrocytoma. *Int J Cancer* 109: 476-479, 2004.
234. Tallen G, Riabowol K, and Wolff JE. Expression of p33ING1 mRNA and chemosensitivity in brain tumor cells. *Anticancer Res* 23: 1631-1635, 2003.
235. Tatsumi T, Herrem CJ, Olson WC, Finke JH, Bukowski RM, Kinch MS, Ranieri E, and Storkus WJ. Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. *Cancer Res* 63: 4481-4489, 2003.
236. Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, Bukowski RM, Mueller-Berghaus J, Kirkwood JM, Kwok WW, and Storkus WJ. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. *J Exp Med* 196: 619-628, 2002.
237. Taylor WR, DePrimo SE, Agarwal A, Agarwal ML, Schonthal AH, Katula KS, and Stark GR. Mechanisms of G2 arrest in response to overexpression of p53. *Mol Biol Cell* 10: 3607-3622, 1999.
238. Thoenes W and Storkel S. [Pathology of benign and malignant renal cell tumors]. *Urologe A* 30: W41-50, 1991.
239. Thoenes W, Storkel S, and Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. *Pathol Res Pract* 181: 125-143, 1986.
240. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. *Science* 267: 1456-1462, 1995.
241. Thrasher JB and Paulson DF. Prognostic factors in renal cancer. *Urol Clin North Am* 20: 247-262, 1993.

242. Tokunaga E, Maehara Y, Oki E, Kitamura K, Kakeji Y, Ohno S, and Sugimachi K. Diminished expression of ING1 mRNA and the correlation with p53 expression in breast cancers. *Cancer Lett* 152: 15-22, 2000.
243. Tomita Y, Nishiyama T, Fujiwara M, and Sato S. Immunohistochemical detection of major histocompatibility complex antigens and quantitative analysis of tumour-infiltrating mononuclear cells in renal cell cancer. *Br J Cancer* 62: 354-359, 1990.
244. Topalian SL, Solomon D, and Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. *J Immunol* 142: 3714-3725, 1989.
245. Townsend SE and Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. *Science* 259: 368-370, 1993.
246. Toyama T, Iwase H, Watson P, Muzik H, Saettler E, Magliocco A, DiFrancesco L, Forsyth P, Garkavtsev I, Kobayashi S, and Riabowol K. Suppression of ING1 expression in sporadic breast cancer. *Oncogene* 18: 5187-5193, 1999.
247. Tsai JP, Chen HW, Cheng ML, Liu HK, Lee YP, Hsieh CL, Luh KT, Wu CW, Hsu LH, Chao TY, Wang WH, Chang CM, and Ting CC. Analysis of host versus tumor interaction in cancer patients: opposing role of transforming growth factor-beta1 and interleukin-6 in the development of in situ tumor immunity. *Immunobiology* 210: 661-671, 2005.
248. Tsang FC, Po LS, Leung KM, Lau A, Siu WY, and Poon RY. ING1b decreases cell proliferation through p53-dependent and -independent mechanisms. *FEBS Lett* 553: 277-285, 2003.
249. Tsavaris N, Baxevanis C, Kosmidis P, and Papamichael M. The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b. *Cancer Immunol Immunother* 43: 94-102, 1996.
250. Tsukamoto T KY, Miyao N, Masumori N, Takahashi A, Yanase M. Interleukin-6 in renal cell carcinoma. *Urol* 148: 1778-1782, 1992.
251. Uchida T, Gao JP, Wang C, Jiang SX, Muramoto M, Satoh T, Minei S, Shimura S, Irie A, Kameya T, and Baba S. Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma. *Urology* 59: 615-620, 2002.
252. Urosevic M, Kurrer MO, Kamarashev J, Mueller B, Weder W, Burg G, Stahel RA, Dummer R, and Trojan A. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. *Am J Pathol* 159: 817-824, 2001.

253. Urosevic M, Willers J, Mueller B, Kempf W, Burg G, and Dummer R. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. *Blood* 99: 609-617, 2002.
254. Uzzo RG, Rayman P, Kolenko V, Clark PE, Bloom T, Ward AM, Molto L, Tannenbaum C, Worford LJ, Bukowski R, Tubbs R, Hsi ED, Bander NH, Novick AC, and Finke JH. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. *Clin Cancer Res* 5: 1219-1229, 1999.
255. Valenzuela MT, Nunez MI, Villalobos M, Siles E, Olea N, Pedraza V, McMillan TJ, and Ruiz de Almodovar JM. Relationship between doxorubicin cell sensitivity, drug-induced DNA double-strand breaks, glutathione content and P-glycoprotein in mammalian tumor cells. *Anticancer Drugs* 6: 749-757, 1995.
256. Van den Hove LE, Van Gool SW, Van Poppel H, Baert L, Coorevits L, Van Damme B, and Ceuppens JL. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma. *Clin Exp Immunol* 109: 501-509, 1997.
257. Vasavada SP, Novick AC, and Williams BR. P53, bcl-2, and Bax expression in renal cell carcinoma. *Urology* 51: 1057-1061, 1998.
258. Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S, Scheper RJ, Meijer CJ, Bloemena E, Ransom JH, Hanna MG, Jr., and Pinedo HM. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. *Lancet* 353: 345-350, 1999.
259. Vieyra D, Senger DL, Toyama T, Muzik H, Brasher PM, Johnston RN, Riabowol K, and Forsyth PA. Altered subcellular localization and low frequency of mutations of ING1 in human brain tumors. *Clin Cancer Res* 9: 5952-5961, 2003.
260. Vieyra D, Toyama T, Hara Y, Boland D, Johnston R, and Riabowol K. ING1 isoforms differentially affect apoptosis in a cell age-dependent manner. *Cancer Res* 62: 4445-4452, 2002.
261. Viret C and Janeway CA, Jr. MHC and T cell development. *Rev Immunogenet* 1: 91-104, 1999.
262. Vogelstein B, Lane D, and Levine AJ. Surfing the p53 network. *Nature* 408: 307-310, 2000.

263. von Roemeling R, Rabatin JT, Fraley EE, and Hrushesky WJ. Progressive metastatic renal cell carcinoma controlled by continuous 5-fluoro-2-deoxyuridine infusion. *J Urol* 139: 259-262, 1988.
264. Waase I, Bergholz M, Iglauer A, Beisert S, Blech M, Schauer A, and Kronke M. Heterogeneity of tumour necrosis factor production in renal cell carcinoma. *Eur J Cancer* 28A: 1660-1664, 1992.
265. Wagner SN, Rebmann V, Willers CP, Grosse-Wilde H, and Goos M. Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma. *Lancet* 356: 220-221, 2000.
266. Wang Q, Redovan C, Tubbs R, Olencki T, Klein E, Kudoh S, Finke J, and Bukowski RM. Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes. *Int J Cancer* 61: 780-785, 1995.
267. Weinschenk T, Gouttefangeas C, Schirle M, Obermayr F, Walter S, Schoor O, Kurek R, Loeser W, Bichler KH, Wernet D, Stevanovic S, and Rammensee HG. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. *Cancer Res* 62: 5818-5827, 2002.
268. Weyand M, Krehmeier M, Fahrenkamp A, Middendorf C, Redmann M, Schwartz C, Konertz W, and Scheld HH. Serial interleukin-6 blood levels early after cardiac transplantation. *Transplant Proc* 24: 2546, 1992.
269. Whiteside TL. Tumor-infiltrating lymphocytes in human solid tumors. *Immunol Ser* 61: 137-148, 1994.
270. Willers J, Urosevic M, Laine E, Geertsen R, Kundig T, Burg G, and Dummer R. Decreased intraindividual HLA class I expression is due to reduced transcription in advanced melanoma and does not correlate with HLA-G expression. *J Invest Dermatol* 117: 1498-1504, 2001.
271. Wyllie AH, Bellamy CO, Bubb VJ, Clarke AR, Corbet S, Curtis L, Harrison DJ, Hooper ML, Toft N, Webb S, and Bird CC. Apoptosis and carcinogenesis. *Br J Cancer* 80 Suppl 1: 34-37, 1999.
272. Yoshida N, Ikemoto S, Narita K, Sugimura K, Wada S, Yasumoto R, Kishimoto T, and Nakatani T. Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma. *Br J Cancer* 86: 1396-1400, 2002.

273. Zeremski M, Hill JE, Kwek SS, Grigorian IA, Gurova KV, Garkavtsev IV, Diatchenko L, Koonin EV, and Gudkov AV. Structure and regulation of the mouse *ing1* gene. Three alternative transcripts encode two phd finger proteins that have opposite effects on p53 function. *J Biol Chem* 274: 32172-32181, 1999.
274. Zinkernagel RM. On immunological memory. *Philos Trans R Soc Lond B Biol Sci* 355: 369-371, 2000.
275. Zinkernagel RM, Bachmann MF, Kundig TM, Oehen S, Pirchet H, and Hengartner H. On immunological memory. *Annu Rev Immunol* 14: 333-367, 1996.